CASE proudly recognizes Swiss Roche for its landmark $50 billion investment in U.S. manufacturing and R&D over the next five years — a powerful testament to the enduring strength of transatlantic economic ties.
This investment is expected to create over 12,000 jobs, including nearly 6,500 in construction and 1,000 permanent roles at new and expanded facilities, significantly boosting the life sciences ecosystem across multiple U.S. states.
Several CASE member states are directly impacted:
- #Kentucky – Strengthening its role in pharmaceutical manufacturing.
- #Indiana – Hosting a new continuous glucose monitoring facility and expanded R&D operations.
Indianapolis is also the U.S. headquarter of Roche Diagnostics. - #New Jersey – Enhancing its pharmaceutical manufacturing capabilities.
- #Pennsylvania – Establishing a state-of-the-art gene therapy manufacturing facility.
- #Florida – Expanding its role in the global healthcare and pharmaceutical sectors
Roche also plans a 900,000 sq ft manufacturing site to support next-gen weight-loss medicines — the largest of its kind in its portfolio.
This milestone reaffirms the critical role of European FDI in driving innovation, job creation, and regional development across the United States. CASE remains committed to fostering these partnerships and promoting investment-driven collaboration between Europe and the U.S.
Read more about this exciting development: https://www.roche.com/media/releases/med-cor-2025-04-22
Logo: Roche SE, Switzerland
More Posts
Weidmüller Group Bolsters U.S. Manufacturing with $16.4m Expansion in Virginia, adding over 100 jobs
